Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Consumer Healthcare's new foam delivery form ofRogaine (minoxidil) carries three years of marketing exclusivity and is patent-protected through 2019, the firm announced Sept. 5

You may also be interested in...



Perrigo Rogaine foam ANDA draws suit

The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)

Perrigo Rogaine foam ANDA draws suit

The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)

Perrigo Rogaine foam ANDA draws suit

The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS099744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel